Secondary Logo

Institutional members access full text with Ovid®

Share this article on:

Resveratrol and breast cancer risk

Levi, F1 2; Pasche, C2; Lucchini, F1; Ghidoni, R3; Ferraroni, M4; La Vecchia, C1 4 5

European Journal of Cancer Prevention: April 2005 - Volume 14 - Issue 2 - p 139-142
Research papers: Breast Cancer

Resveratrol is a non-flavonoid polyphenol that has attracted attention as a potential anticancer agent in vitro and in vivo, but scanty epidemiological data are available. We have therefore analysed the relation between dietary intake of resveratrol and breast cancer risk using data from a case–control study conducted between 1993 and 2003 in the Swiss Canton of Vaud on 369 cases and 602 controls. Compared with the lowest tertile of total resveratrol intake, the multivariate odds ratios (OR) were 0.50 for the intermediate and 0.39 for the highest tertile, and the trend in risk was significant. A significant inverse association was observed for resveratrol from grapes (OR = 0.64 and 0.55), but not for wine. The inverse relation between resveratrol and breast cancer risk was not explained by several potential confounding factors, including detailed allowance for alcohol intake, nor attributable to a non-specific favourable effect of fruit on breast cancer risk.

1Unité d'épidémiologie du Cancer, Institut Universitaire de Médecine Sociale et Préventive, Bugnon 17, 1005 Lausanne, Switzerland

2Registre Vaudois des Tumeurs, Institut Universitaire de Médecine Sociale et Préventive, CHUV-Falaises 1, 1011 Lausanne, Switzerland

3Laboratory of Biochemistry and Molecular Biology, San Paolo University Hospital, via A. di Rudini 8, 20142 Milan, Italy

4Istituto di Biometria e Statistica Medica, Università degli Studi di Milano, Via Venezian 1, 20133 Milan, Italy

5Istituto di Ricerche Farmacologiche ‘Mario Negri’, Via Eritrea 62, 20157 Milan, Italy

Correspondence to: Fabio Levi, Registre Vaudois des Tumeurs, CHUV-Falaises 1, CH 1011 Lausanne, Switzerland. Fax: (+41) 21 3230 303


Received 8 April 2004 Accepted 3 August 2004

© 2005 Lippincott Williams & Wilkins, Inc.